Cytokinetics Reports Material Definitive Agreement & Equity Sales

TL;DR

Cytokinetics inked a deal, took on debt, and sold stock. Big moves ahead.

AI Summary

Cytokinetics, Inc. reported on September 16, 2025, regarding several material events. These include entering into a definitive agreement, creating a direct financial obligation, and unregistered sales of equity securities. The company also disclosed other events and filed financial statements and exhibits.

Why It Matters

This filing indicates significant corporate actions, including potential new financial obligations and equity transactions, which could impact the company's financial structure and shareholder value.

Risk Assessment

Risk Level: medium — The filing details material definitive agreements, financial obligations, and unregistered equity sales, which inherently carry financial and operational risks.

Key Players & Entities

• Cytokinetics, Inc. (company) — Registrant
• September 16, 2025 (date) — Date of earliest event reported
• 350 Oyster Point Boulevard (location) — Principal Executive Offices Address
• South San Francisco, California (location) — Principal Executive Offices City and State
• 94080 (location) — Principal Executive Offices Zip Code
• (650) 624-3000 (phone_number) — Registrant's phone number

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 CYTK The Nasdaq Global Select Marke
• $750.0 million — cs, Incorporated (the "Company") issued $750.0 million aggregate principal amount of its 1.75%
• $100.0 million — option to purchase up to an additional $100.0 million aggregate principal amount of Notes. Th
• $1,000 — ement period") if the trading price per $1,000 principal amount of Notes for each trad
• $68.42 — itial conversion price of approximately $68.42 per share of common stock. The conversi
• $75.0 million — f the outstanding Notes unless at least $75.0 million aggregate principal amount of Notes are
• $50,000,000 — ney with a principal amount of at least $50,000,000; and (vii) certain events of bankruptcy
• $729.4 million — from the offering will be approximately $729.4 million after deducting the initial purchasers'
• $402.5 million — he Company expects to use approximately $402.5 million of the net proceeds from the offering t
• $399.5 million — mon stock in exchange for approximately $399.5 million aggregate principal amount of the 2027

Filing Documents

• d933506d8k.htm (8-K) — 43KB
• d933506dex41.htm (EX-4.1) — 586KB
• d933506dex991.htm (EX-99.1) — 13KB
• d933506dex992.htm (EX-99.2) — 20KB
• g933506g0920013002170.jpg (GRAPHIC) — 2KB
• g933506g0920013002395.jpg (GRAPHIC) — 2KB
• g933506g0920013002498.jpg (GRAPHIC) — 2KB
• g933506g0920013002606.jpg (GRAPHIC) — 2KB
• g933506g0920013002718.jpg (GRAPHIC) — 2KB
• g933506g0920013002847.jpg (GRAPHIC) — 2KB
• g933506g0920020648811.jpg (GRAPHIC) — 3KB
• g933506g58b42.jpg (GRAPHIC) — 5KB
• 0001193125-25-209437.txt ( ) — 931KB
• cytk-20250916.xsd (EX-101.SCH) — 3KB
• cytk-20250916_lab.xml (EX-101.LAB) — 17KB
• cytk-20250916_pre.xml (EX-101.PRE) — 11KB
• d933506d8k_htm.xml (XML) — 3KB

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the offering of the Notes, the potential effects of the Note Exchange Transactions and statements concerning the use of proceeds from the offering. Forward-looking statements represent the Company's current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are market conditions, the satisfaction of the closing conditions related to the offering and risks relating to the Company's business, including in its Annual Report on Form 10-K for the period ended December 31, 2024, filed with the SEC on February 27, 2025 and Quarterly Reports on Form 10-Q for the periods ended March 31, 2025 and June 30, 2025, filed with the SEC on May 6, 2025 and August 7, 2025, respectively, and the future quarterly and current reports that the Company files with the SEC. The forward-looking statements included in this Current Report on Form 8-K speak only as of the date of this Current Report on Form 8-K, and the Company does not undertake to update the statements included in this Current Report on Form 8-K for subsequent developments, except as may be required by law. Item9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 4.1 Indenture, dated as of September 19, 2025, between Cytokinetics, Incorporated and U.S. Bank Trust Company, National Association, as trustee. 4.2 Form of Note, representing the Company's 1.75% Convertible Senior Notes due 2031 (included as Exhibit A to the Indenture filed as Exhibit 4.1). 99.1 Press Release issued by the Company on September 16, 2025. 99.2 Press Release issued by t

View Full Filing

View this 8-K filing on SEC EDGAR